StockData
Filana Therapeutics, Inc. logo

Filana Therapeutics, Inc. (FLNA) stock

FLNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$0.64+0.08 (+14.52%)

Close on Nov 20, 2026Market cap $30.98MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$30.98M
P/E ratio
–
Price to sales
–
Price to book
0.49
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$42.28M
EPS, diluted
-$1.88
Free cash flow
-$32.83M

Trading

Next earnings
Mar 11, 2027 (estimated, before the open)
Previous close
$0.56
Open
$0.59
Day's range
$0.59 – $0.66
Volume
1,332,414
Average volume (20 days)
559,956
Beta (5 years)
0.61
52-week range
$0.39 – $3.45
RSI (14 days)
56.2
Volatility (1 year)
91.0%
Relative volume
0.85×
WACC
8.1%

Market cap history

Month-end market cap since 2011, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 20, 2026. The S&P 500 is measured by the SPY fund.

PeriodFLNAS&P 500DifferenceFLNA per yearS&P 500 per year
1 month-6.9%-10.3%+3.4 pts
3 months-32.0%-9.3%−22.6 pts
Year to date-67.6%+1.9%−69.6 pts
1 year-75.6%+6.9%−82.5 pts
3 years-97.2%+57.5%−154.7 pts-69.6%+16.3%
5 years-98.8%+57.3%−156.1 pts-58.7%+9.5%
10 years-84.7%+269.7%−354.4 pts-17.1%+14.0%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$45.97M

Net income

-$42.28M

EPS, diluted

–

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Filana Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Filana Therapeutics

Pharmaceutical Preparations

Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system disorders. The company's lead drug candidate is simufilam, a proprietary oral small molecule designed to modulate filamin A protein activity. Filana is studying simufilam specifically for the treatment of tuberous sclerosis complex-related epilepsy, a genetic condition that causes non-malignant tumors and frequent treatment-resistant seizures. While the company operates in pharmaceutical research and development, its prospective end users are individuals affected by central nervous system conditions and tuberous sclerosis complex.

Company profile, executives and history

Filana Therapeutics stock: common questions

What is Filana Therapeutics's stock price?

FLNA closed at $0.64 on Nov 20, 2026, up 14.52% on the day. Over the past 52 weeks it traded between $0.39 and $3.45.

What is Filana Therapeutics's market cap?

Filana Therapeutics was worth $30.98M at the close on Nov 20, 2026: the share price times the diluted shares outstanding.

What is FLNA's P/E ratio?

Filana Therapeutics lost money over fiscal 2025 (diluted EPS -$1.88), so it has no meaningful P/E ratio.

Does Filana Therapeutics pay a dividend?

No. Filana Therapeutics has not paid a cash dividend over the last twelve months.

When does Filana Therapeutics report earnings next?

Filana Therapeutics is expected to report Q4 FY2026 results on Mar 11, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has FLNA stock performed over the past year?

Including dividends, FLNA returned -75.6% over the past year, against +6.9% for the S&P 500.

How many FLNA shares are sold short?

6M shares were sold short at the latest FINRA report, 12.31% of the float, or 20.6 days of average trading volume.

Who are Filana Therapeutics's competitors?

Companies most similar to Filana Therapeutics by business, industry and size include CAMP, PRAX, PLRX, OVID, GANX.

See a number that looks wrong?